Effects of invigorating-spleen and anticancer prescription on extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway in colon cancer mice model

Table 1 Grouping and interventions for mice

Group	Number	Dose, g/kg
Control group	8	/
Low-dose group of ISAP	8	9.5
Medium-dose group of ISAP	8	19
High-dose group of ISAP	8	38
Capecitabine group	8	19

ISAP: Invigorating-spleen and anticancer prescription.

Table 2 The effect of invigorating-spleen and anticancer prescription on body weight of mice (mean ± SD, g)

Group	D0	D14	D14 - D0
Control group	20.22 ± 0.01	18.15 ± 0.03a	2.07 ± 0.03
Low-dose group of ISAP	20.47 ± 0.71	18.89 ± 0.34a	1.58 ± 0.83
Medium-dose group of ISAP	20.28 ± 0.02	19.08 ± 0.34a	1.20 ± 0.34
High-dose group of ISAP	20.39 ± 0.05	19.51 ± 0.59a,b,c	0.87 ± 0.07
Capecitabine group	20.46 ± 0.01	16.29 ± 0.08a	4.18 ± 0.06

^aP < 0.05 compared to the control group.

^bP < 0.05 compared to the low-dose group of invigorating-spleen and anticancer prescription (ISAP).

^cP < 0.05 compared to the medium-dose group of ISAP.

ISAP: Invigorating-spleen and anticancer prescription; D0: Day 0; D14: Day 14.

Table 3 The effect of invigorating-spleen and anticancer prescription on tumor inhibition rate of mice

Group	Tumor weight (g; mean ± SD)	Tumor inhibition rate (%)
Control group	1.38 ± 0.12	/
Low-dose group of ISAP	1.22 ± 0.03	0.12 ± 0.02
Medium-dose group of ISAP	1.07 ± 0.34a	0.31 ± 0.08b
High-dose group of ISAP	0.9 ± 0.08a	0.34 ± 0.05b
Capecitabine group	0.53 ± 0.13a	0.59 ± 0.03b

^aP < 0.05 compared to the control group.

^bP < 0.05 compared to the low-dose group of invigorating-spleen and anticancer prescription.

ISAP: Invigorating-spleen and anticancer prescription.